A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche